Id: acc2450
Group: 2sens
Protein: TrkB
Gene Symbol: NTRK2
Protein Id: Q16620
Protein Name: NTRK2_HUMAN
PTM: phosphorylation
Site: Tyr
Site Sequence:
Disease Category: Cancer
Disease: Neuroblastoma
Disease Subtype:
Disease Cellline: SH-SY5Y
Disease Info:
Drug: retinoic acid
Drug Info: "Retinoic acid (also known as tretinoin or vitamin A acid) is a potent metabolite of vitamin A that regulates cell growth, differentiation, and organogenesis by acting as a natural agonist of retinoic acid receptors (RARs) and modulating gene transcription."
Effect: modulate
Effect Info: RA promotes the differentiation and growth inhibition of neuroblastoma cells by upregulating the expression of TrkB receptors and enhancing BDNF-mediated TrkB phosphorylation.
Note: site unclear
Score: 4.0
Pubmed(PMID): 8394722
Sentence Index:
Sentence:

Sequence & Structure:

MSSWIRWHGPAMARLWGFCWLVVGFWRAAFACPTSCKCSASRIWCSDPSPGIVAFPRLEPNSVDPENITEIFIANQKRLEIINEDDVEAYVGLRNLTIVDSGLKFVAHKAFLKNSNLQHINFTRNKLTSLSRKHFRHLDLSELILVGNPFTCSCDIMWIKTLQEAKSSPDTQDLYCLNESSKNIPLANLQIPNCGLPSANLAAPNLTVEEGKSITLSCSVAGDPVPNMYWDVGNLVSKHMNETSHTQGSLRITNISSDDSGKQISCVAENLVGEDQDSVNLTVHFAPTITFLESPTSDHHWCIPFTVKGNPKPALQWFYNGAILNESKYICTKIHVTNHTEYHGCLQLDNPTHMNNGDYTLIAKNEYGKDEKQISAHFMGWPGIDDGANPNYPDVIYEDYGTAANDIGDTTNRSNEIPSTDVTDKTGREHLSVYAVVVIASVVGFCLLVMLFLLKLARHSKFGMKGPASVISNDDDSASPLHHISNGSNTPSSSEGGPDAVIIGMTKIPVIENPQYFGITNSQLKPDTFVQHIKRHNIVLKRELGEGAFGKVFLAECYNLCPEQDKILVAVKTLKDASDNARKDFHREAELLTNLQHEHIVKFYGVCVEGDPLIMVFEYMKHGDLNKFLRAHGPDAVLMAEGNPPTELTQSQMLHIAQQIAAGMVYLASQHFVHRDLATRNCLVGENLLVKIGDFGMSRDVYSTDYYRVGGHTMLPIRWMPPESIMYRKFTTESDVWSLGVVLWEIFTYGKQPWYQLSNNEVIECITQGRVLQRPRTCPQEVYELMLGCWQREPHMRKNIKGIHTLLQNLAKASPVYLDILG

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
NTRK2 ENTRECTINIB Neurotrophic tyrosine kinase receptor inhibitor 4 - neoplasm FDA
ATC
NTRK2 LAROTRECTINIB Neurotrophic tyrosine kinase receptor inhibitor 4 - neoplasm ATC
FDA
NTRK2 LAROTRECTINIB SULFATE Neurotrophic tyrosine kinase receptor inhibitor 4 - neoplasm FDA
NTRK2 ENTRECTINIB Neurotrophic tyrosine kinase receptor inhibitor 4 - non-small cell lung carcinoma EMA
DailyMed
FDA
NTRK2 CENEGERMIN Neurotrophic tyrosine kinase receptor agonist 4 - eye disease ATC
NTRK2 CENEGERMIN Neurotrophic tyrosine kinase receptor agonist 4 - keratitis EMA
FDA
NTRK2 LAROTRECTINIB SULFATE Neurotrophic tyrosine kinase receptor inhibitor 4 - metastasis FDA
NTRK2 LAROTRECTINIB SULFATE Neurotrophic tyrosine kinase receptor inhibitor 4 - cancer FDA
NTRK2 LESTAURTINIB Neurotrophic tyrosine kinase receptor type 2 inhibitor 3 Active, not recruiting acute lymphoblastic leukemia ClinicalTrials
NTRK2 ENTRECTINIB Neurotrophic tyrosine kinase receptor inhibitor 3 Recruiting non-small cell lung carcinoma ClinicalTrials
ClinicalTrials
NTRK2 REPOTRECTINIB Neurotrophic tyrosine kinase receptor type 2 inhibitor 3 Recruiting non-small cell lung carcinoma ClinicalTrials
NTRK2 CENEGERMIN Neurotrophic tyrosine kinase receptor agonist 3 Completed dry eye syndrome ClinicalTrials
ClinicalTrials
NTRK2 LESTAURTINIB Neurotrophic tyrosine kinase receptor type 2 inhibitor 3 Active, not recruiting childhood T acute lymphoblastic leukemia ClinicalTrials
NTRK2 LESTAURTINIB Neurotrophic tyrosine kinase receptor type 2 inhibitor 2 Completed acute myeloid leukemia ClinicalTrials
NTRK2 ENTRECTINIB Neurotrophic tyrosine kinase receptor inhibitor 2 Terminated cutaneous melanoma ClinicalTrials
NTRK2 LESTAURTINIB Neurotrophic tyrosine kinase receptor type 2 inhibitor 2 Completed essential thrombocythemia ClinicalTrials
NTRK2 ENTRECTINIB Neurotrophic tyrosine kinase receptor inhibitor 2 Active, not recruiting invasive lobular carcinoma ClinicalTrials
NTRK2 LESTAURTINIB Neurotrophic tyrosine kinase receptor type 2 inhibitor 2 Completed leukemia ClinicalTrials
NTRK2 ENTRECTINIB Neurotrophic tyrosine kinase receptor inhibitor 2 Recruiting neoplasm ClinicalTrials
ClinicalTrials
ClinicalTrials
NTRK2 LAROTRECTINIB SULFATE Neurotrophic tyrosine kinase receptor inhibitor 2 Recruiting neoplasm ClinicalTrials
NTRK2 TALETRECTINIB Neurotrophic tyrosine kinase receptor inhibitor 2 Recruiting neoplasm ClinicalTrials
NTRK2 LAROTRECTINIB Neurotrophic tyrosine kinase receptor inhibitor 2 Active, not recruiting neoplasm ClinicalTrials
NTRK2 LAROTRECTINIB Neurotrophic tyrosine kinase receptor inhibitor 2 Recruiting neoplasm ClinicalTrials
NTRK2 LESTAURTINIB Neurotrophic tyrosine kinase receptor type 2 inhibitor 2 Completed psoriasis ClinicalTrials
NTRK2 LAROTRECTINIB Neurotrophic tyrosine kinase receptor inhibitor 2 Active, not recruiting multiple myeloma ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
Y 722 N Obesity Phosphorylation 15494731

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: